Online first
Current issue
Archive
Special Issues
About the Journal
Publication Ethics
Anti-Plagiarism system
Instructions for Authors
Instructions for Reviewers
Editorial Board
Editorial Office
Contact
Reviewers
All Reviewers
2023
2022
2021
2020
2019
2018
2017
2016
General Data Protection Regulation (RODO)
RESEARCH PAPER
Is there a rationale for aggressive breast cancer liver metastases resections in Polish female patients? Analysis of overall survival following hepatic resection at a single centre in Poland
1
Department of General, Transplant and Liver Surgery, Medical University, Warsaw, Poland
2
Department of Pathology, Medical University, Warsaw, Poland
3
Department of Radiology, Medical University, Warsaw, Poland
Corresponding author
Eliza Kobryń
Department of General, Transplant and Liver Surgery, Medical University, Warsaw, Poland
Department of General, Transplant and Liver Surgery, Medical University, Warsaw, Poland
Ann Agric Environ Med. 2016;23(4):683-687
KEYWORDS
ABSTRACT
Introduction:
Breast cancer (BC) makes up nearly 26% of malignant tumours worldwide and is the leading cause of cancer-related deaths in European women. With approximately 18,000 new cases of BC diagnosed in Polish women annually, breast cancer liver metastasis (BCLM) is respectively an increasing issue. Recent data found in literature indicates improved survival following liver resection with systemic therapy.
Objective:
The aim of study was to evaluate surgical treatment in patients with isolated BCLM.
Material and Methods:
During 2009–2013, a retrospective study was undertaken and 30 cases analysed. From nearly 2,000 liver resections performed, 11 female patients at the mean age of 59.18 years with BCLM were qualified for surgery.
Results:
The median time between primary and secondary treatment was 3.5 years (1–7). One patient (9.1%) presented an extrahepatic lesion – bone metastasis. The left lobe, right lobe and both lobes of the liver were affected, respectively, in 3 (27.3%), 4 (36.4%) and 4 (36.4%) patients. 5 patients (45.5%) presented single hepatic lesion, in contrast to the maximum number of lesions which equalled 6 in the right lobe. Average hospitalisation period was 13.27 days and discharge on the 11.3 postoperative day. One-year survival was 72.7% (8 patients); therefore, three-year survival was 36.4% (4 patients).
Conclusions:
Oncological centres should assess BCLM patients more openly and qualify them for hepatic resection along with adjuvant systemic treatment in order to improve overall survival. This, however, needs to be studied in a multicentre randomized trial.
Breast cancer (BC) makes up nearly 26% of malignant tumours worldwide and is the leading cause of cancer-related deaths in European women. With approximately 18,000 new cases of BC diagnosed in Polish women annually, breast cancer liver metastasis (BCLM) is respectively an increasing issue. Recent data found in literature indicates improved survival following liver resection with systemic therapy.
Objective:
The aim of study was to evaluate surgical treatment in patients with isolated BCLM.
Material and Methods:
During 2009–2013, a retrospective study was undertaken and 30 cases analysed. From nearly 2,000 liver resections performed, 11 female patients at the mean age of 59.18 years with BCLM were qualified for surgery.
Results:
The median time between primary and secondary treatment was 3.5 years (1–7). One patient (9.1%) presented an extrahepatic lesion – bone metastasis. The left lobe, right lobe and both lobes of the liver were affected, respectively, in 3 (27.3%), 4 (36.4%) and 4 (36.4%) patients. 5 patients (45.5%) presented single hepatic lesion, in contrast to the maximum number of lesions which equalled 6 in the right lobe. Average hospitalisation period was 13.27 days and discharge on the 11.3 postoperative day. One-year survival was 72.7% (8 patients); therefore, three-year survival was 36.4% (4 patients).
Conclusions:
Oncological centres should assess BCLM patients more openly and qualify them for hepatic resection along with adjuvant systemic treatment in order to improve overall survival. This, however, needs to be studied in a multicentre randomized trial.
REFERENCES (34)
2.
Banas T, Juszczyk G, Pitynski K, Nieweglowska D, Ludwin A, Czerw A. Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980–2013): an analysis of population-based data in relation to socioeconomic changes. OnkoTargets Therapy 2016; 7 Sept.
3.
Carsoso F, Costa A, Norton L, Cameron D, Cuffer T, Fallowfield L, et al. 1 st International consensus guidelines for advanced breast cancer (ABC1). Breast 2012; 21: 242–252.
4.
Jemal A, Siegel R, Ward E, Murrau T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007; 57: 43–66.
5.
Zielinski J, Jaworski R, Irga-Jaworska N, Haponiuk I, Jaskiewicz J. The significance of ductoscopy of mammary ducts in the diagnostics of breast neoplasms. Videosurgery Miniinv 2015; 10 (1): 79–86.
6.
Vertriest C, Berardi G, Tomassini F, Broucke RV, Depypere H, Cocquyt V, et al. Resection of Single Metachronous Liver Metastases from Breast Cancer Stage I-II Yeld Excellent Overall and Disease-Free Survival. Single Centre Experience and Review of the Literature. Dig Surg. 2015; 32: 52–59.
7.
Lee YT. Breast carcinoma: pattern of recurrence and metastasis after mastectomy. Am J Clin Oncol. 1984; 7: 443–9.
8.
Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, et al. Predictive Profile-Normogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results Ann Surg Oncol. 2016 Aug 29.
9.
Adam R, Chiche L, Aloia, Ellias D, Salmon RJ, et al. Hepatic Resection for Noncolorectal, Nonendocrine Liver Metastases. Analysis of 1452 patients and development of a prognostic model. Ann Surg. 2006; 244: 524–535.
10.
Insa A, LLuch A, Prosper F, Marguan I, Marginez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999; 56: 67–78.
11.
Hoe AL, Royle GT, Taylor I. Breast liver metastases – incidence, diagnosis and outcome. J R Soc Med. 1991; 84: 714–716.
12.
Polistina F, Constantin G, Febbraro A, Robusto E, Ambrosino G. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg. 2013; 37: 1322–1332.
13.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608: 1–22.
14.
Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008; 34: 378–390.
15.
Li Z, Kang Y. Emerging therapeutic targets in metastatic progression a focus on breast cancer. Pharmacol Ther. 2016; 161: 79–96.
16.
Margonis G A, Buettner S, Sasaki K, Kim Y, Ratii F, Russolilo N, et al. The role of liver-directed surgery in patients with hepatic metastasis from breast cancer: a multi-institutional analysis. HPB (Oxford) 2016; 18: 700–705.
17.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer Analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309–318.
18.
Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumors in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009, April 15.
19.
Martel G, Hawel J, Rekman J, Croome KP, Bertens K, Balaa FK, Hernandez-Alejandro R. Liver Resection for Non-Colorectal, Non-Carcinoid, Non-Sarcoma Metastases: A Multicenter Study; Plos One 2015; March 26.
20.
Sabol M, Donat R, Chvalny P, Dyttert D, Palaj J, Durdik S. Surgical management of breast cancer metastases Neoplasma 2014; 61: 5.
21.
Sadot E, Ser Yee Lee, Sofocleous CT, Solomon SB, Gonen M, Kingham TP, et al. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis A case-control Study with Comparison to Medically Treated Patients. Ann Surg. 2016; 264: 147–154.
22.
Ruiz A, Castro-Betnitez C, Sebagh M, Giaccetti S, Castro-Santa E, Witchers DA, et al. Repeat Hepatectomy for Breast Cancer Liver Metastases. Ann Surg Oncol. 2015; 22: S1057-S1066.
23.
Bacalbasa N, Dima SO, Purtan-Purnichescu R, Herlea V, Popescu I. Role of Surgical Treatment in Breast Cancer Liver Metastases: A Single Center Experience. Anticancer Res. 2014; 34(10): 5563–5568.
24.
Frankel TL, D’Angelica MI. Hepatic resection for colorectal metastases Surg Oncol. 2014; 109: 2–9.
25.
Lee SY, Cheow PC, Teo JY, et al. Surgical treatment of neuroendocrine liver metastases Int J Hepatol. 2012; 2012: 146590.
26.
Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy for bone metastases – single-dose radiotherapy is effective. Duodecim 2002; 118: 1889–1894.
27.
Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International Guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010; 102: 456–463.
28.
Gabriel I, Olejek A. The value of hysteroscopic-based decision-making in uterine abnormalities during tamoxifen intake in breast cancer patients – preliminary report. Videosurgery Miniinv 2014; 9 (2): 258–261.
29.
Stathopoulos GP, Trafalis D, Kaparelou M. Bone metastasis in breast cancer is treated by high-dose tamoxifen. J BUON 2016 Aug; 21(4):1013–1015.
30.
Rennert G, Pinchev M, Gronich N, Saliba W, Flugelman A, Lavi I, et al. Oral bisphosphonates and improved survival of breast cancer. Clin Cancer Res. 2016 Sept 28.
31.
Kamińska M, Ciszewski T, Kukiełka-Budny B. Life quality of women with breast cancer after mastectomy or breast conserving therapy treated with adjuvant chemotherapy. Ann Agric Environ Med. 2015; 22 (4): 724–730.
32.
Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res. 2014; May 45(4): 301–8.
33.
Nowikiewicz T, Nowak A, Wiśniewska M, Wiśniewski M, Zegarski W. Diagnostic value of preoperative axillary lymph node ultrasound assessment in patients with breast cancer qualified for sentinel lymph node biopsy. Videosurgery Miniinv. 2015; 10 (2): 170–177.
34.
Lei L, Wang X, Chen Z. PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer. Adv Clin Exp Med. 2016; 25(2): 377–382.
Share
RELATED ARTICLE
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2024 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
